NASDAQ:GTHX
G1 Therapeutics Inc Stock News
$4.27
-0.220 (-4.90%)
At Close: May 06, 2024
G1 Therapeutics to Release Second Quarter 2022 Financial Results and Provide Business Update on August 3, 2022
09:00am, Wednesday, 20'th Jul 2022
RESEARCH TRIANGLE PARK, N.C., July 20, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporat
COSELA® (Trilaciclib Hydrochloride for Injection) Now Approved in China to Decrease the Incidence of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
02:15pm, Wednesday, 13'th Jul 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., July 13, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the China National Medical Products Ad
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09:20pm, Friday, 01'st Jul 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., July 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exerc
Got $500? 3 Absurdly Cheap Healthcare Stocks That Are Set to Skyrocket
08:45pm, Friday, 01'st Jul 2022 The Motley Fool
Here's why these Fool.com contributors are bullish on Adaptimmune Therapeutics, G1 Therapeutics, and Axsome Therapeutics.
Got $500? 3 Absurdly Cheap Healthcare Stocks That Are Set to Skyrocket
04:45pm, Friday, 01'st Jul 2022
Here's why these Fool.com contributors are bullish on Adaptimmune Therapeutics, G1 Therapeutics, and Axsome Therapeutics.
G1 Therapeutics Announces Addition of Jacks Lee to Board of Directors
11:30am, Tuesday, 28'th Jun 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., June 28, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the appointment of Jacks Lee to its Board o
- Patients Receiving Trilaciclib Experienced a Lower Incidence of Single-Lineage and Multilineage Chemotherapy-Induced Myelosuppressive Events Compared with Patients Receiving Placebo -
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:45pm, Wednesday, 01'st Jun 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., June 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exerc
G1 Therapeutics Named 2022 Life Sciences Public Company of the Year by Triangle Business Journal
02:30pm, Friday, 20'th May 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., May 20, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that it received Triangle Business Journal'
G1 Therapeutics to Participate in the H.C. Wainwright & Co. Global Investment Conference
02:15pm, Wednesday, 18'th May 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., May 18, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey, G1’s Chief Executive Off
G1 Therapeutics to Participate in the H.C. Wainwright & Co. Global Investment Conference
10:15am, Wednesday, 18'th May 2022
RESEARCH TRIANGLE PARK, N.C., May 18, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey, G1's Chief Executive Officer
G1 Therapeutics, Inc. (GTHX) CEO Jack Bailey on Q1 2022 Results - Earnings Call Transcript
03:10pm, Wednesday, 04'th May 2022
G1 Therapeutics, Inc. (NASDAQ:GTHX ) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants Will Roberts - Head-Corporate Communications Jack Bailey - Chief Executive Officer And
G1 Therapeutics (GTHX) Reports Q1 Loss, Tops Revenue Estimates
11:45am, Wednesday, 04'th May 2022 Zacks Investment Research
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of -16.16% and 19.37%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
G1 Therapeutics Provides First Quarter 2022 Financial Results and Operational Highlights
10:30am, Wednesday, 04'th May 2022 GlobeNewswire Inc.
- Achieved $6.9 Million in Total Revenue in the First Quarter of 2022, Including $5.5 Million in Net Revenue from Sales of COSELA™ (trilaciclib) -
G1 Therapeutics (GTHX) Reports Q1 Loss, Tops Revenue Estimates
09:02am, Wednesday, 04'th May 2022
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of -16.16% and 19.37%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
